Savara (SVRA) to Release Earnings on Tuesday

Key Points

• Savara will release Q1 2026 results before the market opens on Tuesday, May 12, with analysts expecting EPS of ($0.14) and revenue of $0.5M; an earnings call is scheduled for Wednesday, May 13 at 4:00 PM ET.
• Analyst sentiment is mixed but leans positive—MarketBeat shows a "Moderate Buy" consensus and a $9.13 average price target, even after a recent quarterly EPS miss and divergent ratings from Strong Buy to Sell.
• Company focus and pipeline: Savara is a clinical‑stage biopharma developing therapies for rare respiratory diseases, and its lead candidate Molgradex is under regulatory review for autoimmune pulmonary alveolar proteinosis (PAP).

Savara (NASDAQ:SVRA - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Savara to post earnings of ($0.14) per share and revenue of $0.50 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings data on Friday, March 13th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). On average, analysts expect Savara to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Savara Stock Down 2.4%

SVRA traded down $0.13 on Tuesday, hitting $5.17. The company had a trading volume of 274,500 shares, compared to its average volume of 1,543,079. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.85 and a quick ratio of 11.85. Savara has a 52-week low of $1.89 and a 52-week high of $7.01. The stock has a fifty day simple moving average of $5.46 and a 200-day simple moving average of $5.41. The firm has a market capitalization of $1.06 billion, a P/E ratio of -9.76 and a beta of 0.28.

Analysts Set New Price Targets

SVRA has been the subject of several research analyst reports. Wall Street Zen lowered shares of Savara from a "hold" rating to a "sell" rating in a report on Saturday, March 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a research report on Tuesday, April 21st. HC Wainwright reissued a "buy" rating on shares of Savara in a research report on Monday, March 16th. Oppenheimer initiated coverage on Savara in a research report on Friday, April 24th. They set an "outperform" rating and a $11.00 price objective for the company. Finally, William Blair set a $10.00 price objective on Savara in a research report on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $9.13.

Hedge Funds Weigh In On Savara

Large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its holdings in shares of Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock valued at $37,000 after purchasing an additional 9,463 shares during the last quarter. Xponance LLC purchased a new position in shares of Savara in the 4th quarter worth about $66,000. CIBC Bancorp USA Inc. purchased a new position in shares of Savara in the 3rd quarter worth about $44,000. Prudential Financial Inc. purchased a new position in shares of Savara in the 2nd quarter worth about $30,000. Finally, BNP Paribas Financial Markets raised its position in shares of Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock worth $31,000 after purchasing an additional 4,626 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

About Savara

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.